Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bausch + Lomb Corp.
Industry Sector: HealthTechnology
CEO: Brenton L. Saunders, MBA
Number Of Employees: 13,500
Enterprise Value: $11,044,508,000
PE Ratio: -16.84
Exchange/Ticker 1: NYSE:BLCO
Exchange/Ticker 2: N/A
Latest Market Cap: $5,354,034,688
BioCentury | Jan 18, 2025
Politics, Policy & Law
Diabetes, cancer drugs dominate CMS’s new price negotiation list
Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027
BioCentury | Oct 24, 2024
Politics, Policy & Law
FDA must be protected from politics, say Califf, ex-agency leaders
Celebrating Richard Pazdur’s 25th anniversary, former FDA commissioners say political pressures have intensified
BioCentury | Feb 21, 2024
Management Tracks
Papa succeeds Miller as Emergent’s CEO
Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA
BioCentury | Oct 12, 2023
Product Development
Slimmed down Novartis is now poised to grow value, says CEO Narasimhan
How Vas Narasimhan is managing change as he continues to chart a new course for the pharma
BioCentury | Jul 1, 2023
Finance
June 30 Quick Takes: Genfit hits but falls short of competitor in primary biliary cholangitis
Plus: Novartis sells front-of-eye portfolio to B&L, and updates from argenx, Black Diamond, KangaBio and more
BioCentury | Jun 1, 2023
Data Byte
At least 15 PDUFA dates on FDA’s calendar for June
Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | Apr 13, 2023
Management Tracks
SVB’s Sabow to lead HSBC tech, healthcare business
Plus: Century revamps C-suite amid CEO departure and updates from Bausch + Lomb, Gennao, Celares, Sherlock, Viridian and more
BioCentury | Apr 6, 2023
Management Tracks
After leading CinCor to exit, de Garidel finds next CEO role at Abivax
Plus: INKEF’s Bulthuis joins Syncona and updates from Rocket, NGM, SparingVision, Walden and more
BioCentury | Sep 7, 2022
Finance
Sept. 7 Quick Takes: Arch-backed Orbital launches with RNA platform
Plus Arpeggio raises $17M series A for transcriptional mechanisms, and updates from Equillium, BoomRay, Zealand and more
BioCentury | Jul 8, 2022
Finance
2Q22 Wrap: it could be worse
Bleeding continued in biopharma in second quarter, with median market caps down in all tiers
Items per page:
1 - 10 of 10